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ABSTRACT 
 
RNA interference (RNAi) is an endogenous process that regulates expression of genes and corresponding 
proteins to maintain homeostasis in diverse organisms. Non-coding RNAs (ncRNAs) including both long 
and short ncRNAs are widely expressed and levels of some specific microRNAs are different in tumor and 
non-tumor tissues. RNAi has been invaluable for unraveling critical pathways involved in cancer develop-
ment, growth and metastasis and has identified critical tumor-type specific gene targets for chemotherapy. In 
addition, the development of new derivatized small inhibitory RNAs and more efficient methods of their de-
livery will facilitate the future development of these ribonucleotides as cancer chemotherapeutic agents. 
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INTRODUCTION 
 
RNA interference (RNAi) is a relatively new discovery for 
inhibiting gene expression and is considered as one of the 
most important recent discoveries in molecular oncology.  
RNAi is already a valuable and well-used research tool in 
the analysis of molecular mechanisms for many diseases 
including cancer and this is because it allows researchers 
to silence the expression of specific genes, much like an-
tisense  technology,  but  with  higher  specificity  and  effi-
cacy. RNAi was first identified as a defense mechanism 
against  the  invasion  of  foreign  genes  in  the  nematode 
Caenorhabditis elegans (Fire et al, 1998) and has subse-
quently been discovered in diverse eukaryotes such as in-
sects,  plants,  fungi  and  vertebrates.  RNAi  is  a  post-
transcriptional  process  that  can  effect  gene  silencing 
through chromatin remodeling, blocking protein synthesis 
and cleaving specifically targeted mRNA. The manner by 
which RNAi produces gene-silencing is primarily depend-
ent  on  the  structure  of  the  initiating  RNA  [complete 
(siRNA) or incomplete (miRNA)] homology to the target 
mRNA (Figure 1). The classical RNAi pathway is initiated 
by double-stranded RNAs (dsRNAs) that are homologous 
to the gene being silenced. These dsRNAs are processed 
by  an enzyme called Dicer (a cellular ribonuclease  III), 
which generates duplexes of approximately 21 nucleotides 
with 3’-overhangs. These are referred to as small inhibi-
tory or interfering RNAs (siRNA). These fragments acti-
vate a protein complex called RISC (RNA-Induced Silenc-
ing  Complex)  and  lead  to  degradation  of  the  specific 
mRNA through the action of a protein called Slicer (Argo-
naute-2)(Liu et al, 2004b; Song et al, 2004) and it has been 
shown  recently  in  cytoplasmic  extracts  from  human 
HEK293 and Drosophila S2 cell that these processes of 
dsRNA unwinding, RISC assembly as well as target RNA 
cleavage  are  ATP-independent  (Matranga  et  al,  2005; 
Rand et al, 2005). 
 
In mammalian cells, siRNA molecules are capable of 70-
100 % silencing of a specific gene and has become a new 
and powerful alternative to other nucleic-acid-based tools 
such as antisense oligonucleotides and ribozymes to ana-
lyze loss-of function phenotypes. Although the specificity 
of gene silencing is a significant advantage of RNAi tech-
nology over other gene-targeting approaches, progress in 
the areas of  delivery and duration  of the effect are still 
required.  Conventional  methods  of  physical  or  chemical 
methods for transfection can be used for delivering siRNA  
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duplexes into mammalian cells, however the resulting effi-
ciency of the RNAi can be highly variable. 
 
More prolonged gene silencing has been achieved by ex-
pressing siRNAs from plasmid vectors that contain specific 
promoters  (Lee  et  al,  2002;  Paul  et  al,  2002;  Sui  et  al, 
2002). The most effective plasmid construct is the one that 
expresses the siRNA as a short hairpin (shRNA) precursor 
structure of around 70 nucleotides (Paddison et al, 2002). 
These shRNA precursors expressed from RNA polymerase 
promoters II or III are processed in to a fully functional 
siRNA  by an  enzyme  called  Drosha  (RNase  III  enzyme 
involved  in  processing  pri-microRNA  and  shRNA) 
(Brummelkamp et al, 2002b). Viral vectors have also been 
developed  for  more  stable  and  long-term  expression  of 
shRNAs. For example, a recombinant adenovirus system 
has been used to target p53 mRNA in MCF-7 breast cancer 
and A549  lung  carcinoma  cells  and this  was a proof  of 
principle for a prospective siRNA applications in functional 
genomics and cancer gene therapy (Shen et al, 2003). 
 
RNAi AND CANCER 
 
RNAi is a  highly promising technology for gene therapy 
application in treatment of different cancers and preliminary 
results  of  trials  with  siRNAs  targeted  against  VEGF  for 
treatment of macular degeneration disease are encouraging. 
However, in systemic disease, RNAi, like other forms of 
gene therapy, is challenged by the method of delivery and 
stability  in  vivo.  In  oncology,  the  initial  applications  of 
RNAi  have  focused  on  targeting  dominant  mutant  onco-
genes, amplified, translocated and viral oncogenes in order 
to elucidate their function and interactions with other genes 
and this will be discussed in the next section of this review. 
The use of RNAi in probing the functions of various genes 
in several tumors has also facilitated the systematic search 
for new drug targets. On the other hand, the effects of exist-
ing drugs such as imatinib and rapamycin have been en-
hanced by silencing their resistance-associated gene BCR-
ABL using RNAi technology (Chen et al, 2004).  
 
Role of RNAi in tumorgenesis 
Cancer is a multistep genetic and epigenetic disease with a 
complex  etiology.  Cancer  cells  have  been  characterized 
with several defects such as mutations, down-regulation, 
over-expression  and  deletions  of  oncogenes  and  tumor 
suppressor genes. Different experimental approaches have 
been used to compare tumor cells to normal cells and have 
shown that defects in non-coding RNAs (ncRNAs) might 
be important. The first example of large ncRNA associated 
with tumors was the H19 gene (Hao et al, 1993) and there 
is now a growing list of ncRNA transcripts implicated in 
different types of cancer. NcRNAs that are implicated in 
cancer include both small and large RNAs and it has been 
reported that large ncRNAs can generate one or more mi-
croRNAs (miRNA). For example, the ncRNA BIC which 
has been implicated in growth control and oncogenesis in 
cancer cells generates two miRNA, one of which miR155, 
is  over  expressed  in  in  Burkitt  and  B  cell  lymphomas 
(Metzler et al, 2004; Eis et al, 2005). For this reason both 
long and short ncRNAs implicated in cancer will be dis-
cussed in this review.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The classical RNAi and miRNA pathways: Long dsRNAs [and short hairpin RNA (shRNA)] are processed by Dicer to 
give siRNAs. The duplexed siRNAs are unwound as they assemble to the RNA-induced silencing complex (RISC). The single-
stranded siRNA guides the endonuclease activity of the activated RISC to the homologous site on the mRNA, cleaving the mRNA. 
In miRNA pathway: The pre-miRNA is expressed in the nucleus from endogenous long transcripts and is processed into ~70-nt hair-
pins by the RNase III family member Drosha to become the pre-miRNA. The pre-miRNA is exported to the cytoplasm by Exportin 5 
and is further cleaved by Dicer into the mature miRNA. The miRNA is loaded into RISC where it guides the protein complex to a 
site on the mRNA that has only partial sequence complementarity to the miRNA, leading to repression of translation. 
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Long ncRNA 
It  has  been  reported  that  Prostate  Specific  Gene  1 
(PCGEM1) ncRNA gene is over expressed in prostate tu-
mors compared to normal and primary tumor specimens 
(Srikantan  et  al,  2000).  In  addition,  over  expression  of 
PCGEM1 in LNCaP and in NIH3T3 cells enhanced cell 
proliferation and dramatically increased in colony forma-
tion suggesting a biological role for PCGEM1 in prostate 
tumorigenesis (Petrovics et al, 2004). Interestingly, some 
of  these  ncRNAs  have  been  used  as  very  sensitive  and 
specific markers for the detection of specific tumors. For 
example, one study with patient urine samples suggested 
that DD3 ncRNA gene which is overexpressed in prostate 
cancer can be  used as a molecular marker for the diagno-
sis of this disease (Tinzl et al, 2004). In addition, another 
study has considered this ncRNA as a target for further 
cancer therapies because it is not expressed in any normal 
human tissues, including breast, bladder, testis, gastroin-
testinal  organ,  and  musculoskeletal  tissue    and  this  has 
been confirmed by reverse transcription-polymerase chain 
reaction analysis (Schalken et al, 2003). Metastasis Asso-
ciated in Lung Adenocarcinoma Transcript 1 ncRNA gene 
or the MALAT-1 is over expressed in NSCLC (Non Small 
Cell  Lung  Carcinoma)  and  has  been  characterized  as  a 
highly  reliable  prognostic  parameter  for  NSCLC  patient 
survival,  MALAT-1  has  been  used  for  identification  of 
early-stage NSCLC patients who are at high risk to  de-
velop metastases (Ji et al, 2003). Some ncRNAs such as 
small dendritic non-translatable RNA BC1 are selectively 
expressed  in  tumor  cells,  but  not  in  the  corresponding 
normal  tissues  (Chen  et  al,  1997b).  In  a  similar  study, 
BC200 ncRNA, a brain-specific small cytoplasmic RNA, 
is expressed in  human carcinomas of the  breast, cervix, 
esophagus,  lung,  ovary,  parotid,  and  tongue,  but  not  in 
their corresponding non-tumor tissues (Chen et al, 1997a). 
 
Short ncRNA 
At present, there are no reports of endogenously expressed 
siRNAs in mammals. However, miRNAs have been identi-
fied from various organisms and cell types (Lagos-Quintana 
et al, 2003; Lim et al, 2003a; Lim et al, 2003b). Differential 
expression of miRNAs has been reported in several human 
cancers including chronic lymphocytic leukemia (Calin et 
al,  2002),  colorectal  neoplasia  (Michael  et  al,  2003)  and 
Burkitt’s  lymphoma  (Metzler  et  al,  2004)  and  human 
miRNAs are  usually located  at fragile sites and  genomic 
loci involved in several cancers (Calin et al, 2004).  
 
Some of these miRNA, have been identified based on their  
homology and proximity to known genes (Pasquinelli et al, 
2000); other miRNAs have been characterized by scoring 
candidate  miRNA  stem  loops  and  pairing  with  known 
miRNA genes (Ambros et al, 2003; Lim et al, 2003b). Cur-
rently, there are 326 confirmed miRNAs in humans, and 
computational searches estimate that the total count might 
be  as  high  as  one  thousand  (Bentwich  et  al,  2005; 
Berezikov et al, 2005). In another recent study, Bead-based 
hybridization method has been used as a profiling method 
for the analysis of expression of all known miRNAs across 
a  large  number  of samples  of  human  normal  and  tumor 
tissues including bladder, breast, follicular lymphoma, kid-
ney,  liver,  melanoma,  mesothelioma,  pancreas,  prostate, 
stomach, uterus, acute myelogenous leukaemia and others 
(Lu et al, 2005). The miRNA profiles were highly informa-
tive, they showed a general downregulation of miRNAs in 
tumors  compared  with  normal  tissues  and  a  differential 
expression of nearly all miRNAs across cancer types which 
suggest that unlike mRNA expression, a small number of 
miRNAs might be sufficient to classify human cancers and 
reflects the differentiation state of the tumors. 
 
Application  of  oligonucleotide  microchip  methods  have 
identified a total of 281 miRNA precursor sequences and 
have also  quantified their expression (Liu et al,  2004a). 
This  approach  can  also  be  utilized  to  compare  miRNA 
expression in normal or malignant tissues. For example, 
miR-143 and miR-145 consistently display lower steady-
state levels at the adenomatous and cancerous stages  of 
colorectal  neoplasia  (Michael  et  al,  2003).  Importantly, 
deletion and/or down-regulation of miR-15a and miR-16a 
has  frequently  been  detected  in  patients  with  B-CLL 
(Calin et al, 2002). Recently, it was suggested that both 
miR-15a and miR-16 potentiate the normal apoptotic re-
sponse  by  targeting  the  anti-apoptotic  gene  BCL-2 
(Cimmino et al, 2005). In this case, these miRNAs func-
tion as tumor suppressors, and re-expression of miR-15a–
16 in lymphoma cells promotes apoptosis. Expression of 
let-7 miRNAs were decreased in lung cancer patients and 
were an independent factor for prediction of patient sur-
vival  (Takamizawa  et  al,  2004).  Another  study  showed 
that over-expression of let-7 miRNAs in lung adenocarci-
noma cell lines inhibits lung cancer cell growth in vitro 
(Takamizawa et al, 2004) indicating an important role for 
let-7  miRNAs  in  lung  tumorigenesis.  A  recent  study, 
showed  an  elevated  expression  of  the  mature  miRNAs 
collectively denoted as mir-17–92 in primary lymphomas 
and a wide range  of tumor derived cell lines (He et al, 
2005; Tagawa and Seto, 2005). 
 
Transcriptional  regulation  of  miRNA  expression  and 
modulation  of  their  target  genes  has  been  investigated. 
One study has shown that c-Myc transcription factor acti-
vates  expression  of  a  cluster  of  six  miRNA  on  human 
chromosome  13 and two  of these,  miR-17-5p and miR-
20a, negatively regulate E2F, another transcription factor. 
E2F1 is a down stream target of c-Myc that promotes cell 
cycle progression. This report identifies miRNAs as tar-
gets of c-Myc that tightly regulates c-Myc-mediated cellu-
lar  proliferation  by  decreasing  E2F1  expression 
(O'Donnell et al, 2005). 
 
The recent identification of new classes of ncRNAs impli-
cated in important steps of cancer initiation and progres-
sion reinforces the importance of these transcripts in the 
process  of tumorigenesis.  Moreover,  some  of the  newly 
identified  ncRNAs can  now be used as targets for drug 
development and for early diagnosis and prognosis of can-
cer suggesting that some  of these  transcripts may  be as 
important as protein-coding genes in cancer biology. 
 
Application of RNAi in studying multistep carcinogenesis 
pathways 
RNAi has become the method of choice for specific gene 
silencing in cell culture. The success of this approach de-
pends on the effectiveness of siRNA delivery and design 
of the siRNA sequence (McManus and Sharp, 2002; Ban- 
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tounas et al, 2004). Different biochemical, pharmacologi-
cal, and histological assays have been used to determine 
the effects of siRNA inhibition of specific genes and to 
analyze the phenotypic changes in cells. Currently, the use 
of  siRNA  to  characterize  gene  function,  and  potential 
therapeutic drug targets is a highly promising application 
for this technology (Lu et al, 2003). Selective gene knock-
down can be used to identify critical genes and/or path-
ways that can be targeted by siRNA, drugs and their com-
binations for treatment of various disease including can-
cers. To reach these goals, RNAi has been used to investi-
gate  many  of  the  important  stages  in  tumor  formation, 
growth and metastasis and some of these applications are 
highlighted below.  
 
Oncogenes and tumor suppressor genes 
RNAi has been employed to investigate gene function and 
molecular  mechanisms  of tumorgenesis and progression. 
For example, cellular oncogenes (c-onc) are normal cellu-
lar  genes  with the  potential  to  enhance  cell  growth  and 
tumor formation. Numerous proteins such as growth fac-
tors and their receptors, signal transducers and transcrip-
tion factors associated with tumor initiation and progres-
sion are encoded by c-onc. For example the Ras gene fam-
ily is frequently mutated in human cancers, particularly in 
pancreatic  and  colon  carcinoma.  Ras  genes  are  guanine 
nucleotide  binding  proteins  which  include  K-RAS,  H-
RAS, and N-RAS and these proteins are associated with 
the inner plasma membrane and transduce external signals 
to  regulate  intracellular  functions.  In  CAPAN-1  human 
pancreatic  cells  down-regulation  of  K-RAS  protein  by 
RNAi leads to loss of anchorage-independent growth and 
tumorigenesis  (Brummelkamp  et  al,  2002a).  Single  and 
combinatorial c-onc siRNAs combined with cationic lipid 
complexes have been transfected into HeLa, lung adeno-
carcinoma, hepatoma, ovarian carcinoma, and melanoma 
cells.  The  results  showed  that siRNAs-dependent  down-
regulation of  bcl-2, cdk-2, mdm-2, pkc-α, tgf-β1, H-ras, 
vegf, and gfp mRNA expression  differentially suppressed  
proliferation  of these cancer cell lines (Yin et al,  2003) 
demonstrating  that many oncogenes are potential molecu-
lar targets for human cancer treatment by siRNAs. 
 
Tumour  suppressor  genes  (TSGs)  generally  inhibit  cell 
proliferation and tumor formation and mutation or loss-of-
function of these genes drives normal cells toward cancer 
cell phenotype.  For example the somatic inactivation  of 
Retinoblastoma (Rb) tumor suppressor gene leads to en-
hanced tumor growth. RNAi technology has been used to 
investigate a new program of dE2F/RBF- dependent tran-
scription, in which dE2F2/RBF complexes repressed on-
cogene expression in SL2 cells. Each component  of the 
dE2F/dDP/RBF pathway was silenced by RNAi and ex-
amination  of  changes  in  gene  expression  showed  a  re-
markable division of labor between family members. Clas-
sic E2F targets, encoding functions required for cell cycle 
progression, are expressed in cycling cells and are primar-
ily dependent on dE2F1and RBF1 (Dimova et al, 2003). 
 
Another TSG locus that has been studied using RNAi is 
INK4A. This locus is  often inactivated in  human cancer 
and encodes for p14ARF and p16INK4A that inhibit cell 
growth through p53 and pRb, respectively. The function of 
the human INK4A genes has been investigated in normal 
and  tumorigenic growth and it has been  shown that the 
suppression of p16INK4A expression did not affect cell 
proliferation but promoted their growth and transformation 
with loss of p53 expression (Agami, 2002). 
 
DNA damage and genome stability 
Biological  responses  to  DNA  damage  are  mediated  by 
multiple DNA repair pathways, or cell cycle checkpoint 
responses  that  inhibit  cellular  pathways  leading  to  cell 
death.  Cells  routinely  experience  several  kinds  of  DNA 
lesions  and  these  include  mismatches  that  occur  during 
replication, various types of base damage and single and 
double DNA strand breaks (Jeggo et al, 1991; Hoeijmak-
ers,  2001;  Bedford  and  Dewey,  2002).  Cells  deal  with 
DNA  double  strand  breaks  by  two  known  processes, 
namely  non-homologous  end joining  (NHEJ)  which  can 
lead to deletions and chromosomal rearrangements (Dai et 
al, 2003) and homology-directed repair (HDR) or repair by 
homologous  recombination  [Reviewed  in  (Jeggo  et  al, 
1991; Hoeijmakers, 2001; Bedford and Dewey, 2002)]. 
 
Defects in DNA repair enzymes may not affect cell viabil-
ity, but result in genomic instability, and thereby increase 
the rate of genetic changes and the rate of tumor formation 
(Vogelstein  and  Kinzler,  2004).  SiRNA  technology  has 
been applied to the DNA repair field  through knockdown 
of  the  ATR  interacting  protein  (ATRIP)(Cortez  et  al, 
2001). ATR (Ataxia-Telangiectasia and Rad3-Related) is a 
member of the phosphatidylinositol kinase family which is 
involved in DNA damage signaling and cell cycle check-
points.  While  the  related  cell  cycle  checkpoint  protein 
ATM  (Ataxia-Telangiectasia  Mutated) from AT  patients 
(characterized by cerebellar ataxia, x-ray hypersensitivity 
and a predisposition to malignancy) has been investigated, 
studies on ATR were not well characterized due to lack of 
ATR−/− cell lines since ATR knock-out mice exhibit em-
bryonic lethality (Brown and Baltimore, 2000). Three dif-
ferent  siRNAs  targeting  different  regions  of  the  ATRIP 
mRNA were used for gene silencing and the results reveal 
that  ATRIP  is  phosphorylated  by  ATR,  regulates  ATR 
expression,  and  is  an  essential  component  of  the  DNA 
damage checkpoint pathway (Cortez et al, 2001). SiRNAs 
against ATR have also been used in human lymphoblast 
cell lines and show participation of ATR in chromosome 
fragile site stability (Casper et al, 2002). SiRNA has also 
been used to knock down the p53-binding protein (53BP1) 
and  showed  that  this  protein plays a  role  in  checkpoint 
responses and phosphorylation of 53BP1 after DNA dam-
age by ionizing radiation leading to rapid relocalization, 
along with Mre11, and gammaH2AX, to the sites of DNA 
damage (Morales et al, 2003). 
 
Rad-51 gene is another gene of interest in DNA repair 
field that has been studied using the RNAi technology. 
Suppression of rad-51 in C. elegans showed that rad51 
played a roles  in  sister chromatids repair after both en-
dogenous  and  exogenous  double-strand  breaks  (DSB) 
formation during meiosis, but not as 'pairing centers' for 
meiotic synapsis (Takanami et al, 2003). Rad-51 RNAi 
did not affect chromosome appearance if DSB was pre-
vented  by  spo-11  or  mre-11  mutations.  Chromosomal 
DNA degradation is a hallmark of apoptosis and repre- 
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sents a key point in cell death execution. Recently, seven 
additional  cell  death-related  nucleases  were  identified  
using  an  RNAi-based  functional  genomic  approach 
(Parrish and Xue, 2003). For example CPS-6 and NUC-1 
nucleases comprise two independent pathways that con-
tribute to cell death induced by degrading chromosomal 
DNA. The application of RNAi in this area of research 
has elucidated the mechanism of genome instability and 
also it has suggested some molecular targets for clinical 
applications. 
 
Angiogenesis and metastasis 
Tumor angiogenesis involves new blood vessels formation 
and is mediated by changes in the balance between angio-
genesis factors and angiogenesis inhibitors (Bergers and 
Benjamin, 2003). Angiogenesis can be suppressed by his-
tone  deacetylase  (HADC)  inhibitors.  RECK  is  a  mem-
brane-anchored glycoprotein that negatively regulates ma-
trix metalloproteinases (MMPs) and inhibits tumor metas-
tasis and angiogenesis. Inhibition of RECK by siRNAs in 
CL-1  human  lung  cancer  cells  abolished  the  inhibitory 
effect of HDAC inhibitor trichostatin A (TSA) on MMP-2 
activation (Liu et al, 2003). This study provided insights 
on how HDACs suppress tumor invasion and angiogenesis 
and provided a new strategy for cancer therapy. The CXC 
chemokine receptor-4 (CXCR4) is over-expressed in the 
highly invasive MDA-MB-231 human breast cancer cells 
and may play a role in the metastasis of this cell line in 
animal  models.  Using  an  inducible  siRNAs  expression 
system,  it  was  shown    that  knockdown  of  CXCR4  in 
MDA-MB-231cells  resulted  in  significant  inhibition  of 
breast cancer cell migration in vitro (Chen et al, 2003). 
 
Expression of the angiogenic factor VEGF in cancer cell 
lines is regulated through Sp protein interactions with sev-
eral proximal GC-rich motifs in the VEGF promoter (Shi 
et  al,  2001;  Abdelrahim  et  al,  2004).  Sp  proteins  and 
Krüppel-like factors (KLFs) are a growing family of tran-
scription factors that  bind GC-rich motifs and modulate 
gene transcription (Safe and Abdelrahim, 2005). There is 
emerging evidence that Sp proteins are critical factors in 
tumor development, growth and metastasis; however, most 
studies have focused primarily on Sp1 protein/mRNA ex-
pression and not other member of this family. It was ini-
tially reported  that Sp1 was overexpressed in pancreatic 
tumors compared to normal tissues, and there was a corre-
lation between Sp and VEGF expression in pancreatic tu-
mors and cancer cell lines (Shi et al, 2001). A recent study 
in this laboratory used siRNAs to further investigate the 
role of Sp1 and other Sp proteins in regulation of VEGF 
expression  in  pancreatic  cancer  cells  (Abdelrahim  et  al, 
2004).  The results show that the proximal GC-rich sites in 
the VEGF promoter are required for expression of VEGF 
in  Panc1  cells;  however,  results  of  RNA  interference 
showed that multiple Sp proteins are involved in VEGF 
regulation (Figure 2). Sequential knockdown of Sp1, Sp3 
or Sp4 by RNAi showed that all three proteins regulated 
transactivation in pancreatic cancer cells transfected with 
the pVEGF1, pVEGF2 and pVEGF3 constructs containing 
VEGF  promoter  inserts  (Figure  2).  Sp4  knockdown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regulation of VEGF expression in Panc-1 pancreatic cancer cells.  Cells were transfected with various VEGF promoter 
constructs, transfected with scramble siRNA (non-specific) or with small inhibitory RNAs for Sp1 (iSp1), Sp3 (iSp3) or Sp4 (iSp4), 
and luciferase activity determined as previously reported (Abdelrahim et al, 2004).
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decreased  activity  (≥  50%)  in  cells  transfected  with  all 
three constructs, whereas Sp1 and Sp3 differentially regu-
lated  gene  expression in cells  transfected  with pVEGF1 
and pVEGF3, respectively. These results indicate that Sp1, 
Sp3 and Sp4 cooperatively regulate VEGF expression and 
the promoter analysis suggested differential activation by 
these  proteins  in  the  proximal  and  distal  regions  of  the 
promoter. Sp4 expression has not been extensively inves-
tigated in cancer cells, and results from these RNAi studies 
suggest that the metastatic and growth potential of pancre-
atic tumors may also be dependent on levels of Sp4. 
 
Another  important  factor  that  regulates  expression  of 
VEGF and other angiogenic proteins is hypoxia-inducible 
factor (HIF). HIF is α/β heterodimeric DNA binding com-
plex that directs an extensive transcriptional response in-
volving the induction of genes with important roles in sev-
eral aspects of tumor angiogenesis, invasion and metastasis. 
HIF-1α is the O2-regulated subunit while HIF-1 β is consti-
tutively expressed. Overexpression of the HIF-1α subunit, 
due to intratumoral hypoxia or genetic alterations, has been 
demonstrated in common human cancers. One study has 
demonstrate  that  HIF-1α  overexpression  stimulates  Ma-
trigel invasion by HCT116 human colon carcinoma cells 
whereas  this  process  is  inhibited  by  a  small  interfering 
RNAs targeted against HIF-1α. The same siRNA approach 
was used to show that HIF-1 regulates the expression of 
genes  encoding  cathepsin  D;  matrix metalloproteinase  2; 
urokinase  plasminogen  activator  receptor  (uPAR);  fi-
bronectin 1; keratins 14, 18, and 19; vimentin; transforming 
growth factor α; and autocrine motility factor, which are 
proteins that play important roles in the pathophysiology of 
tumor invasion (Krishnamachary et al, 2003).  
 
To date, three HIF-1 isoforms have been described, with 
the best characterized being HIF-1α and HIF-2α. The indi-
vidual roles of these two alternative subunits are not fully 
understood due to close similarities between them. SiRNA 
approach  has  been  used  successfully to  determine  func-
tional differences between HIF-1α and HIF-2α in different 
human cell lines (Warnecke  et al,  2004). In  this report, 
RNase protection assays revealed that HIF-1α knockdown 
in HeLa cells reduced hypoxia-stimulated mRNA induc-
tion of glucose transporter 1 (GLUT-1), lactate dehydro-
genase A (LDH-A), VEGF, carbonic anhydrase IX (CA 
IX),  and  HIF  prolyl  hydroxylase  2  (PHD2)  by  40–60% 
while HIF-2α knockdown had no effect on these HIF tar-
get  genes.  On  the  other  hand,  the  study  showed  that 
mRNA induction of erythropoietin (EPO) after exposure 
of Hep3B cells to hypoxia was almost abolished by the 
HIF-2α siRNA whereas HIF-1α knockdown had no effect.   
 
RNAi has also been used to study the viability of endothe-
lial cells when Tie-2-dependent signaling is interrupted by 
RNAi. Tie-2 is a small molecule inhibitor of endothelial 
cell specific tyrosine kinases. Decreased expression of Tie-
2 in endothelial cells  by RNAi resulted in loss of cell 
viability and phosphotidylinisitol-3kinase (PI3K) activity 
and increased expression of  thrombospondin (endogenous 
anti-angiogenic  proteins)  (Niu  et  al,  2004).  These  data 
show that Tie-2 mediated activation PI3Kinase/Akt is in-
volved in angiopoietin signaling, which in turn represses 
thrombospondin  expression  suggesting  that  blocking  of 
Tie-2 in endothelial cells might be an effective inhibitor of  
angiogenesis. 
 
Other important proteins involved in tumor invasion and 
metastasis  are  matrix  metalloproteases  (MMP)-9  and 
cathepsin B which work by influencing matrix degrada-
tion. Cell-cell interactions between human microvascular 
endothelial cells werer significantly reduced when MMP-9 
and  cathepsin  B  genes  expression  were  suppressed  by 
hairpin RNAs in SNB19 cells (Lakka et al, 2004). It has 
been  demonstrated  that  direct  intratumoral  injections  of 
plasmid DNA expressing hairpin RNAs for MMP-9 and 
cathepsin B significantly inhibited established glioma tu-
mor growth and invasion in vivo and intraperitoneal injec-
tions  of  these  constructs  completely  repressed  pre-
established tumors for up to 4 months (Liu et al, 2003). 
This was the first report to demonstrate that simultaneous 
suppression of MMP-9 and cathepsin B genes by RNAi 
can be  used for the treatment  of human  gliomas.  These 
results show that RNAi can be used to selectively target 
genes that are involved in tumor growth, invasion and me-
tastasis  and  this  technique  holds  great  promise  for  the 
clinical treatment of a wide variety of human tumors.  
 
Tumor cell survival and apoptosis 
The rate of tumor growth and expansion is controlled by 
the balance between cell proliferation/survival and apop-
tosis and in normal cells these processes are strictly regu-
lated. However, apoptosis is disrupted in cancer cells and 
tumors (Wilda et al, 2002; Schmitt, 2003) and cell cycle 
proteins required for cell survival and proliferation are up-
regulated or continuously activated.   
 
Sp1  also  plays  a  role  in  regulating  hormone-
responsiveness of several genes in breast cancer cells as-
sociated with cell proliferation and cycle progression (cy-
clin  D1,  E2F1,  c-fos,  transforming  growth  factor  α), 
purine/pyrimidine synthesis and metabolism [thymidylate 
synthase, adenosine deaminase, DNA polymerase α, car-
bamylphosphate  synthetase/aspartate  carbamyltrans-
ferase/dihydroorotase (CAD)], angiogenesis (VEGF), and 
anti-apoptosis (bcl-2) [Reviewed in (Safe and Abdelrahim, 
2005)].  These  genes  are  regulated  by  ERα/Sp1-3  and 
knockdown of Sp1 and other Sp proteins resulted in loss of 
hormone induced gene expression. RNA interference us-
ing small inhibitory RNAs for Sp1, Sp3 and Sp4 has also 
used to investigate the role of these proteins in growth of 
Panc-1 pancreatic cancer cells (Abdelrahim et al, 2004). 
Results summarized in Figure 3 show that transfection of 
Panc-1 cells with nonspecific small inhibitory RNA (iScr) 
did not affect distribution of Panc-1 cells in G0/G1, G2/M 
or  S  phases  of  the  cell  cycle,  whereas  small  inhibitory 
RNA for Sp1 (iSp1) decreased the percentage of cells in 
G2/M and S phase and increased the percentage in G0/G1. 
This  response  was  also  accompanied  by  decreased  Rb 
phosphorylation and reflects the overall decrease in multi-
ple genes associated with Sp1-dependent growth.  In addi-
tion, dramatic response was observed in cells transfected 
with  small inhibitory  RNA for Sp3 (iSp3) in which  the 
percentage  of  cells  in  G0/G1  and  S  phase  increased  by 
~20% and decreased by ~17%, respectively. These results 
were  explained  after  subsequent  analysis  of  several  cell 
cycle genes after iSp3 treatment. In Panc-1 and other panc-  
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Figure 3.  Effects of Sp proteins on cycle phase distribution in Panc-1 cells. Cells were transfected with Scramble siRNA (iScr, non-
specific) or with small inhibitory RNA for iSp1, iSp3 or iSp4, and the percentage distribution of Panc-1 cells in G0/G1, G2/M and S 
phases of the cell cycle were determined by FACS analysis (Abdelrahim et al, 2004).  Sp3 knockdown increased G0/G1 and de-
creased S phase due to increased expression of p27. 
 
 
 
reatic cancer cell lines transfected with iSp3 the cyclin-
dependent kinase inhibitor p27 was upregulated showing 
that Sp3 enhanced cell growth through inhibiting p27 ex-
pression. On the other hand, transfection with small inhibi-
tory RNA for Sp4 (iSp4) showed a minimum effect on cell 
cycle progression and p27 protein expression.  
 
Apoptosis  has  also  been  extensively  studied  by  RNAi. 
Antiapoptotic factors have been over expressed in many 
tumors and that might explain the resistance of some tu-
mors  to  apoptosis  induced  by  cytotoxic  drugs  (Schmitt, 
2003). For example, the livin (ML-IAP, KIAP) gene is an 
antiapoptotic factor and silencing of livin in MeWo mela-
noma  and  HeLa  cervical  carcinoma  cells  strongly  in-
creased apoptotic rates in response to different proapop-
totic  stimuli and  this was linked to caspase-3 activation 
(Crnkovic-Mertens et al, 2003; Schmitt, 2003). This study 
showed that functional inhibition of specific antiapoptotic 
factors by siRNA may provide a rational basis for the de-
velopment  of  novel  therapeutic  strategies  and  the  livin 
gene  was  identified  as  a  promising  molecular  target for 
therapeutic inhibition. 
 
Bcl-2 and xIAP are antiapoptotic factors and the sensitiv-
ity  of  MCF-7  breast  cancer  cells  to  treatment  with  the 
drugs etoposide and doxorubicin is  increased after silenc-
ing of bcl-2 or xIAP by siRNA (Lima et al, 2004). Treat-
ment of these cells with both siRNAs decreases the num-
ber of viable cells and increased cellular apoptosis. These 
studies suggest that combination therapy that includes tra-
ditional  chemotherapies  coadministered  with  specific 
siRNAs may be a highly effective therapy for cancer.  
 
RNAi  has  also  been  used  to  determine  which  apoptotic 
genes  regulate  the survival  of HCT116  colorectal  carci-
noma  cells.    Bcl-2  and  Bcl-xL
  are  silenced  in  isogenic 
clones of p53+/+, p53 / , Bax+/  ,
 Bax /  cells. In 
this study authors identified a novel proapoptotic function 
of p53
 that does not require activation by genotoxic agents 
and it appeared to be constitutively suppressed by Bcl-2. 
In  addition  Bcl-2  induced  massive  p53-dependent  apop-
tosis which required Bax and caspase 2 as essential apop-
totic  mediators.
  RNAi  showed  that  this  Bcl-2/p53  func-
tional  interface  represents
  a  key  regulator  of  apoptosis 
which  can  be  activated  by  targeting
  Bcl-2  in  colorectal 
carcinoma cells (Jiang and Milner, 2003).  
 
It is clear that RNAi has greatly facilitated the identifica-
tion and the study of components of apoptosis and survival 
pathways and this will facilitate identification of specific 
gene targets for the improving the effectiveness of cancer 
therapies.  
 
Therapeutic potential of siRNA in cancer 
The ability of RNAi to silence disease-associated genes in 
cell culture and animal models has spurred development 
of  RNAi-based reagents for clinical applications to treat 
diseases including cancer (Howard, 2003; Wall and Shi, 
2003). SiRNAs are readily synthesized with low produc-
tion costs compared to protein or antibody therapies. In 
addition, siRNAs have favorable pharmacokinetic proper-
ties  and  can  be  delivered  to  a  wide  range  of  organs 
(Braasch et al,  2004).  However,  their  stability in blood 
and delivery methods are challenges that must be solved 
for developing effective RNAi reagents for cancer ther-
apy.  Several  groups  have  been  investigating  the  use  of 
alternative backbone and nucleotide modifications to im-
prove the clinical properties of these reagents. For exam-
ple,  by  conjugating  the  3’-end  of  the  sense  strand  of 
siRNA with cholesterol through a pyrrolidine linker has 
markedly  improved  the  pharmacological  properties  of 
siRNA  molecules  (Soutschek  et al,  2004).  The  Choles-
terol-conjugated  siRNA  are  more  resistant  to  nuclease 
degradation,  exhibit  increased  stability  in  blood  by  in-
creasing binding to human serum albumin and show in-
creased uptake into liver. Another study has shown that 
boranophosphate modified  siRNAs  were  10 times  more 
nuclease  resistant  than  unmodified  siRNAs  (Hall  et  al, 
2004). In addition, boranophosphate siRNAs were more 
potent  than  unmodified  siRNAs  and  appeared  to  act 
through the standard RNAi pathway. As an alternative to 
backbone  modifications  other  groups  have  improved 
siRNA stability and delivery in vivo by complexing them 
with polyethyleneimine (PEI) (Urban-Klein et al, 2005) or 
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atelocollagen (Minakuchi et al, 2004). For example, in a 
subcutaneous mouse tumor model, intraperitoneal admini-
stration of siRNAs complexed with PEI led to the deliv-
ery  of  intact  siRNAs  into  tumors  (Urban-Klein  et  al, 
2005).  Another  group  has  constructed  self-assembling 
nanoparticles  with  siRNA  and  PEI  PEGylated  with  an 
Arg-Gly-Asp peptide ligand attached to the distal end of 
the polyethylene glycol (PEG) as a means to target tumor 
neovasculature-expressing  integrins  (Schiffelers  et  al, 
2004). Treatment of tumor-bearing mice with this com-
plex  by  intravenous  administration  resulted  in  selective 
tumor uptake, siRNA sequence-specific inhibition of pro-
tein expression within the tumor, and inhibition of both 
tumor angiogenesis and growth. The results showed that 
siRNAs  can  be  targeted  at  two  levels:  tumor  tissue-
selective  delivery  via  the  nanoparticle  ligand  and  gene 
pathway selectivity via the siRNA oligonucleotide. 
 
Topical  gels  have  also  been  used  to  deliver  siRNAs  to 
cells and could open the way for dermatological applica-
tions, as well as the treatment for cervical cancer (Jiang et 
al., 2004).  Intradermal administration of nucleic acids via 
gene guns have also been used to deliver siRNA in vivo 
to  enhance  cancer  vaccine  potency  (Kim  et  al.,  2005). 
Coadministration  of  DNA  vaccines  encoding  human 
papillomavirus  type  16  E7  with  siRNAs  targeting  key 
proapoptotic proteins Bak and Bax prolonged the lives of 
antigen-expressing dendritic cells in the draining lymph 
nodes,  enhanced  antigen-specific  CD8(+)  T-cell  re-
sponses, and elicited potent antitumor effects against an 
E7-expressing tumor model in vaccinated mice. 
 
Systemic administration of siRNA has also been used to 
target tumor growth and angiogenesis. Efficient delivery 
of  siRNA  targeting  VEGF  into  tumors  by  systemic 
intrperitoneal administration at low doses (125 µg/kg/day) 
in saline was observed (Filleur et al., 2003). This treat-
ment  resulted  in  a  robust  inhibition  of  the  endogenous 
VEGF expression  and  produced  a  marked  inhibition  of 
fibrosarcoma  tumor  cells  growth.  No  side-effects  were 
detected in the animals or in specific tissue/organs sug-
gesting that this route of siRNA administration is highly 
effective. 
 
CONCLUSIONS 
 
RNA interference and the function of non-coding RNAs 
represent one of the major scientific discoveries of the past 
decade. The endogenous functions of these ribunucleotides 
remain to be further discovered and the application of spe-
cific gene targeting by small inhibitory RNAs will play an 
important future role as another important treatment option 
for cancer and other diseases. 
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